Abstract
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycaemia, insulin resistance, and impaired glucose regulation. Metformin remains a commonly prescribed first-line pharmacological agent for its management. However, some patients continue to experience inadequate glycaemic control, leading to research into complementary treatment approaches. In Ayurveda, T2DM shares several clinical features with Madhumeha, described under the broader category of Prameha. This article reviews the available clinical research on selected Ayurvedic preparations administered alongside Metformin, including Trikgud, Madhumehari Ghana Vati, and a standardized aqueous extract of Neem (Azadirachta indica). It also discusses a registered clinical trial investigating Triphaladi Kashaya as an add-on intervention with Metformin and Nishatriphala Ghan Capsules with Metformin. The published studies have examined parameters such as fasting blood glucose, postprandial blood glucose, glycated haemoglobin, insulin resistance, and selected metabolic and inflammatory markers. However, differences in formulation composition, study design, sample size, and accompanying lifestyle interventions must be considered while interpreting the findings. Safety aspects, including renal and hepatic function, gastrointestinal tolerance, product standardization, and the possibility of altered blood glucose levels, are also important during combined treatment. Overall, the available research provides preliminary clinical information, but further well-designed trials are required to establish the effectiveness and safety of these combinations.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by persistent elevation of blood glucose levels due to insulin resistance and progressive impairment of pancreatic beta-cell function. It can affect several organ systems and may lead to complications involving the kidneys, eyes, peripheral nerves, cardiovascular system, and blood vessels. Appropriate glycaemic control, dietary regulation, physical activity, and regular clinical monitoring are important components of its management. Metformin is a commonly prescribed oral antidiabetic medicine belonging to the biguanide group. It primarily reduces hepatic glucose production and improves insulin sensitivity. Despite its established role in diabetes management, some patients do not achieve their desired glycaemic targets with Metformin alone. This has encouraged research into additional treatment approaches that may be used alongside conventional antidiabetic therapy. In Ayurveda, several clinical features of T2DM resemble those described under Madhumeha, which is included within the broader classification of Prameha. Ayurvedic descriptions of Prameha involve disturbances in Doshas, particularly Kapha, along with Meda, Kleda, Agni, and different bodily channels (Srotas). The management approach includes dietary regulation, physical activity, correction of metabolic disturbances, and the use of appropriate medicinal preparations. The combination of selected Ayurvedic preparations with Metformin has become an area of clinical investigation. Some studies have evaluated herbal or herbo-mineral preparations in patients continuing their conventional antidiabetic medication. These investigations provide an opportunity to examine changes in glycaemic parameters and other metabolic outcomes. However, the findings must be interpreted according to the actual intervention, study methodology, and safety information available.
Understanding The Ayurvedic Perspective Of Madhumeha
In Ayurveda, Prameha is described as a group of twenty disorders classified according to the involvement of the three Doshas and the characteristics of urine, comprising ten types of Kaphaja Prameha, six types of Pittaja Prameha, and four types of Vataja Prameha. Madhumeha is classified under Vataja Prameha and is characterized by urine having properties resembling Madhu (honey). Its pathogenesis involves disturbances in Doshas, Dhatus, Agni, and Srotas. Increased Kapha Dosha is associated with heaviness, reduced physical activity, and tissue accumulation, while disturbances in Meda Dhatu (adipose tissue) and Kleda (body fluids and moisture) play important roles in disease development. Impairment of Agni (digestive and metabolic capacity) affects nutrient transformation and utilization, whereas Srotodushti (abnormalities of body channels) interferes with normal physiological functions. Ayurvedic management of Madhumeha emphasizes appropriate dietary practices, regular physical activity, and the selection of suitable medicinal preparations. These principles provide a basis for investigating Ayurvedic interventions alongside conventional antidiabetic medicines.
Role Of Metformin In Type 2 Diabetes Mellitus
Metformin belongs to the biguanide class of antidiabetic medicines and is widely used in the management of Type 2 Diabetes Mellitus (T2DM). Its principal actions include suppression of hepatic gluconeogenesis, thereby reducing excessive glucose production by the liver, improvement of peripheral insulin sensitivity to enhance glucose utilization by tissues, and modulation of intestinal glucose handling. It also influences cellular energy-regulating pathways, including AMP-activated protein kinase (AMPK), which plays an important role in glucose and lipid metabolism. Metformin generally does not stimulate insulin secretion directly and therefore has a relatively low risk of hypoglycaemia when used alone. Common adverse effects include nausea, diarrhoea, abdominal discomfort, and other gastrointestinal disturbances. Its use also requires consideration of renal function and other clinical factors. Research into the addition of Ayurvedic preparations to Metformin aims to evaluate their potential additional effects on glycaemic control and metabolic parameters. Such combinations require careful assessment because the composition, pharmacological properties, and quality of individual preparations may differ considerably.
Standardized Neem Leaf-And-Twig Extract Alongside Metformin
Neem (Azadirachta indica) is a medicinal plant investigated for its potential antidiabetic and metabolic activities. Its leaves and twigs contain several bioactive constituents, including flavonoids, limonoids, and other phytochemicals. Compounds such as quercetin and nimbolide have attracted research interest because of their antioxidant, anti-inflammatory, and metabolic effects. Experimental investigations have explored the possible influence of Neem extracts on glucose utilization, insulin sensitivity, and oxidative stress. In the clinical study discussed above, a standardized aqueous extract of Neem leaves and twigs was used in different dose strengths, allowing assessment of its effects alongside ongoing Metformin therapy. Importantly, the findings apply specifically to the standardized extract investigated and should not automatically be extrapolated to other Neem formulations or preparations.
A randomized, double-blind, placebo-controlled clinical study published in 2020 evaluated a standardized aqueous extract of Neem (Azadirachta indica) leaves and twigs in patients with T2DM who were already receiving Metformin therapy. The study included 80 participants who received one of the following interventions:
- Neem extract 125 mg twice daily.
- Neem extract 250 mg twice daily.
- Neem extract 500 mg twice daily.
- Matching placebo.
The treatment period was twelve weeks. The researchers assessed fasting blood glucose, postprandial blood glucose, HbA1c, insulin resistance, endothelial function, oxidative stress, inflammatory markers, platelet aggregation, and lipid profile. The study reported reductions in fasting and postprandial blood glucose, HbA1c, and insulin resistance in the Neem extract groups compared with placebo. Improvements were also reported in endothelial function and selected inflammatory and oxidative stress markers. No significant effect on the lipid profile was observed. The participants tolerated the intervention, and no episodes of hypoglycaemia were reported during the study. The preparation used in this investigation was a proprietary standardized aqueous extract of Neem leaves and twigs. Its composition and extraction method should not be considered equivalent to all Neem powders, decoctions, seed preparations, or commercially available Neem products. The study was also limited by its relatively small sample size, single-centre design, and short treatment duration. This investigation provides direct clinical evidence of a standardized Neem extract being evaluated alongside ongoing Metformin therapy. Nevertheless, further studies are needed to confirm its long-term effectiveness and safety. (5)
Parameters Investigated During Combined Treatment
The available clinical investigations have examined several parameters to understand the possible effects of Ayurvedic preparations used alongside Metformin.
Glycaemic Control
Fasting blood glucose, postprandial blood glucose, and HbA1c are important parameters for assessing glycaemic control. These measurements help determine changes in blood glucose levels over different periods. The Trikgud, Madhumehari Ghana Vati, and Neem extract studies included these parameters in their clinical assessments.
Insulin Resistance
Insulin resistance is an important feature of T2DM. Some of the reviewed studies evaluated insulin resistance using biochemical parameters such as the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Changes in these measurements may provide additional information about metabolic responses during treatment.
Cardiometabolic Parameters
Body weight, body mass index, waist circumference, lipid profile, and other metabolic measurements may be assessed during clinical studies. These parameters provide information beyond blood glucose levels and help evaluate broader metabolic changes.
Clinical Features Of Prameha
Ayurvedic clinical investigations may also assess subjective features such as excessive thirst, frequent urination, increased appetite, weakness, and lethargy. These observations can be recorded alongside objective biochemical measurements to provide a wider assessment of the patient’s clinical condition. The results of individual studies should not be combined as though they evaluated identical interventions. Differences in formulation composition, treatment duration, dietary measures, yoga, and study populations can influence the observed outcomes.
Safety Considerations During Co-Administration
The use of Ayurvedic preparations alongside Metformin requires appropriate clinical supervision. The following considerations are important:
- Blood glucose monitoring: Fasting and postprandial blood glucose levels should be monitored after introducing an additional preparation. This helps identify unexpected changes in glycaemic control.
- HbA1c assessment: Periodic HbA1c evaluation is important for assessing longer-term glycaemic response.
- Gastrointestinal tolerance: Metformin may cause nausea, diarrhoea, abdominal discomfort, and other digestive symptoms. Additional preparations may also produce gastrointestinal disturbances, requiring appropriate monitoring.
- Renal function: Serum creatinine and estimated glomerular filtration rate (eGFR) should be assessed because renal function is important for the safe use of Metformin.
- Hepatic safety: Liver function assessment may be appropriate depending on the preparation, its composition, and the patient’s clinical condition.
- Formulation quality: Preparations should be obtained from reliable sources and should undergo appropriate identification, standardization, and testing for contaminants. Herbo-mineral preparations require particular attention to their metal content and quality-control standards.
- Potential changes in blood glucose: Additional glucose-lowering effects may alter the patient’s glycaemic response, particularly when other antidiabetic medicines are also being used. Medication adjustments should only be made by the treating healthcare professional.
Patients should not discontinue or reduce Metformin independently when starting an Ayurvedic preparation. The decision to use a combination should be individualized and accompanied by suitable clinical and biochemical monitoring.
Conclusion
The co-administration of selected Ayurvedic preparations with Metformin is an emerging area of clinical research in the management of T2DM. Published studies have investigated Trikgud, Madhumehari Ghana Vati as part of an integrated Ayurveda treatment programme, and a standardized aqueous extract of Neem leaves and twigs in patients receiving Metformin. A registered clinical trial has also been designed to evaluate Triphaladi Kashaya as an add-on preparation and Nishatriphala Ghan Capsules with Metformin. The available findings provide preliminary information regarding changes in glycaemic parameters, insulin resistance, and selected clinical and metabolic measurements. However, the interventions differ considerably in their composition and study design. In particular, the results of integrated treatment programmes cannot be attributed solely to Ayurvedic medicine when dietary modifications and yoga are also included. Similarly, findings from a standardized Neem extract cannot automatically be generalized to other Neem preparations. Further well-designed, adequately powered clinical trials with standardized formulations, clearly defined treatment protocols, longer follow-up periods, and comprehensive safety assessments are required. An evidence-based approach should maintain the established role of Metformin while carefully evaluating the additional contribution and safety of each Ayurvedic preparation.
